Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.
Inotek Pharmaceuticals Corp ITEK shares were trading sharply higher by $9.30 (190 percent) at $14.60 in Thursday's session. The catalyst for the rally is the announcement of a positive end-of-phase 2 meeting with FDA and Phase 4 development for Trabodenoson, a novel treatment for glaucoma.
In addition, Cowen hopped on the bandwagon and raised its price target all the way to $40.
After a sharply higher open ($8.32 vs. Wednesday's close of $5.23), it retreated to $7.66 before heading into the stratosphere. So far, the rally has taken the issue beyond its former all-time high ($6.20) to $16.75 before falling back under $15.
The rally is taking place on monster volume. So far, 41.1 million shares compared to its 20-day average of a meager 2 million shares as the close approaches.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.